That's a bunch of BS. I wish I would have noticed that fraud. You can't demand that of shareholders. What a joke. I've been holding this POS for what seems to be, forever . . .based on some idiot's opinion of the company when it had something to do with children's toys. My God how times have changed.
So, why the recent volume? No market news. . .no information to investors. . .nothing. Gotta love these pink sheet stocks.
Peace,
So, why the recent volume? No market news. . .no information to investors. . .nothing. Gotta love these pink sheet stocks.
Peace,
Recent JANX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 09:02:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:56:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:22:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:15:41 PM
- Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development • Business Wire • 04/27/2026 08:01:00 PM
- Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 • Business Wire • 04/16/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/13/2026 08:05:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:02:23 PM
- Janux secures $35 million milestone payment from Bristol Myers Squibb • IH Market News • 04/01/2026 02:01:33 PM
- Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment • Business Wire • 04/01/2026 12:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2026 09:47:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:10:46 PM
- Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights • Business Wire • 02/26/2026 09:01:00 PM
- Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 • Business Wire • 02/17/2026 12:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/06/2026 09:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:01:40 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:00:24 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/26/2026 09:20:12 PM
- Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer • Business Wire • 01/26/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/23/2026 09:08:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 09:30:59 PM
- Janux Therapeutics jumps on new collaboration with Bristol Myers Squibb • IH Market News • 01/22/2026 01:39:50 PM
- Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors • Business Wire • 01/22/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2026 02:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2026 02:00:12 AM
